Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression
Idiopathic pulmonary fibrosis (IPF) is thought to involve inflammatory cells and reactive oxygen species (ROS), such as superoxide anion radical (O2·−). There is currently no effective treatment of IPF. We previously developed a human serum albumin (HSA)–thioredoxin 1 (Trx) fusion protein (HSA-Trx)...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
American Society for Pharmacology and Experimental Therapeutics
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/32658 |
| _version_ | 1848753724207398912 |
|---|---|
| author | Tanaka, R. Watanabe, H. Kodama, A. Chuang, Victor Ishima, Y. Hamasaki, K. Tanaka, K. Mizushima, T. Otagiri, M. Maruyama, T. |
| author_facet | Tanaka, R. Watanabe, H. Kodama, A. Chuang, Victor Ishima, Y. Hamasaki, K. Tanaka, K. Mizushima, T. Otagiri, M. Maruyama, T. |
| author_sort | Tanaka, R. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Idiopathic pulmonary fibrosis (IPF) is thought to involve inflammatory cells and reactive oxygen species (ROS), such as superoxide anion radical (O2·−). There is currently no effective treatment of IPF. We previously developed a human serum albumin (HSA)–thioredoxin 1 (Trx) fusion protein (HSA-Trx) designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an antioxidative and anti-inflammatory protein. In this study, we examined the therapeutic effect of HSA-Trx on an IPF animal model of bleomycin (BLM)-induced pulmonary fibrosis. A pharmacokinetic study of HSA-Trx or Trx in BLM mice showed that the plasma retention and lung distribution of Trxc was markedly improved by fusion with HSA. A weekly intravenous administration of HSA-Trx, but not Trx, ameliorated BLM-induced fibrosis, as evidenced by a histopathological analysis and pulmonary hydroxyproline levels. HSA-Trx suppressed active-transforming growth factor (TGF)-β levels in the lung and inhibited the increase of inflammatory cells in bronchoalveolar lavage fluid, pulmonary inflammatory cytokines, and oxidative stress markers. An in vitro EPR experiment using phosphate-buffered saline–stimulated neutrophils confirmed the O2·− scavenging ability of HSA-Trx. Furthermore, post-treatment of HSA-Trx had a suppressive effect against BLM-induced fibrosis. These results suggest that HSA-Trx has potential as a novel therapeutic agent for IPF, because of its long-acting antioxidative and anti-inflammatory modulation effects. |
| first_indexed | 2025-11-14T08:29:04Z |
| format | Journal Article |
| id | curtin-20.500.11937-32658 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T08:29:04Z |
| publishDate | 2013 |
| publisher | American Society for Pharmacology and Experimental Therapeutics |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-326582017-09-13T15:25:36Z Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression Tanaka, R. Watanabe, H. Kodama, A. Chuang, Victor Ishima, Y. Hamasaki, K. Tanaka, K. Mizushima, T. Otagiri, M. Maruyama, T. Idiopathic pulmonary fibrosis (IPF) is thought to involve inflammatory cells and reactive oxygen species (ROS), such as superoxide anion radical (O2·−). There is currently no effective treatment of IPF. We previously developed a human serum albumin (HSA)–thioredoxin 1 (Trx) fusion protein (HSA-Trx) designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an antioxidative and anti-inflammatory protein. In this study, we examined the therapeutic effect of HSA-Trx on an IPF animal model of bleomycin (BLM)-induced pulmonary fibrosis. A pharmacokinetic study of HSA-Trx or Trx in BLM mice showed that the plasma retention and lung distribution of Trxc was markedly improved by fusion with HSA. A weekly intravenous administration of HSA-Trx, but not Trx, ameliorated BLM-induced fibrosis, as evidenced by a histopathological analysis and pulmonary hydroxyproline levels. HSA-Trx suppressed active-transforming growth factor (TGF)-β levels in the lung and inhibited the increase of inflammatory cells in bronchoalveolar lavage fluid, pulmonary inflammatory cytokines, and oxidative stress markers. An in vitro EPR experiment using phosphate-buffered saline–stimulated neutrophils confirmed the O2·− scavenging ability of HSA-Trx. Furthermore, post-treatment of HSA-Trx had a suppressive effect against BLM-induced fibrosis. These results suggest that HSA-Trx has potential as a novel therapeutic agent for IPF, because of its long-acting antioxidative and anti-inflammatory modulation effects. 2013 Journal Article http://hdl.handle.net/20.500.11937/32658 10.1124/jpet.112.201814 American Society for Pharmacology and Experimental Therapeutics unknown |
| spellingShingle | Tanaka, R. Watanabe, H. Kodama, A. Chuang, Victor Ishima, Y. Hamasaki, K. Tanaka, K. Mizushima, T. Otagiri, M. Maruyama, T. Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| title | Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| title_full | Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| title_fullStr | Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| title_full_unstemmed | Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| title_short | Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| title_sort | long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression |
| url | http://hdl.handle.net/20.500.11937/32658 |